Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: A pilot clinical study

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 39, Issue 1, 2014, Pages 25-31

  Chen, Kai Jie ^a,b   Chen, Wan Yi ^b   Chen, Xia ^b   Jia, Yi Ming ^b   Peng, Gui Qin ^b   Chen, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING UNIVERSITY CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Drug interaction; Hepatoprotective; Magnesium isoglycyrrhizinate; Ovarian cancer; Paclitaxel; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLYCYRRHIZIC ACID DERIVATIVE; HEMOGLOBIN; MAGNESIUM ISOGLYCYRRHIZINATE; NITROGEN; PACLITAXEL; UNCLASSIFIED DRUG; UREA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER PROTECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEUTROPHIL COUNT; OVARY CARCINOMA; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS; SAPONINS; TRITERPENES;

EID: 84897093434     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-013-0136-y     Document Type: Article

References (39)

1. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H (1997) The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79(8):1494-1500 (Pubitemid 27154778)
2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34-43 (Pubitemid 43048949)
3. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2001) Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 3(3):301-306 (Pubitemid 32962892)
4. Briasoulis E, Karavasilis V, Tzamakou E, Piperidou C, Soulti K, Pavlidis N (2006) Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. Anticancer Drugs 17(10):1219-1222 (Pubitemid 44673403)
5. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL II, Meisner BC, Armstrong DK, Frick KD (2007) Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol 106(3):476-481 (Pubitemid 47302480)
6. Cheng Y, Zhang J, Shang J, Zhang L (2009) Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro. Pharmacology 84(3):183-190
7. de Jongh FE, de Wit R, Verweij J, Sparreboom A, van den Bent MJ, Stoter G, van der Burg ME (2002) Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 38(15):2005-2013
8. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320-1329
9. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54(15):4026-4035 (Pubitemid 24258105)
10. Huizing MT, Sparreboom A, Rosing H, van Tellingen O, Pinedo HM, Beijnen JH (1995) Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 674(2):261-268 (Pubitemid 26005553)
11. Jiko M, Yano I, Okuda M, Inui K (2005) Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. Pharm Res 22(2):228-234 (Pubitemid 40487206)
12. Kiso Y, Tohkin M, Hikino H, Hattori M, Sakamoto T, Namba T (1984) Mechanism of antihepatotoxic activity of glycyrrhizin. I: effect on free radical generation and lipid peroxidation. Planta Med 50(4):298-302 (Pubitemid 14008705)
13. Kurata T, Tamura T, Shinkai T, Ohe Y, Kunitoh H, Kodama T, Kakinuma R, Matsumoto T, Kubota K, Omatsu H, Nishiwaki Y, Saijo N (2001) Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. Jpn J Clin Oncol 31(3):93-99 (Pubitemid 32377324)
14. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH (2006) Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 12(20 Pt 1):6125-6132 (Pubitemid 44703778)
15. Landrum LM, Hyde J Jr, Mannel RS, McMeekin DS, Moore KN, Walker JL (2011) Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol 122(3):527-531
16. Liebmann J, Cook JA, Mitchell JB (1993) Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 342(8884):1428
17. Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R (2000) Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Gynecol Oncol 79(1):28-32
18. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH (2001) Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84(1):42-47 (Pubitemid 32102502)
19. Mao YM, Lu LG, Cai X, Wu SM, Chen CW, Fu QC, Cao AP, Chen HZ, Zeng MD (2009a) Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases with high ALT level: a randomized, double-blind, placebo controlled, mult-i center, dose-finding study. Chin Hepatol 14(6):442-445
20. Mao YM, Zeng MD, Chen Y, Chen CW, Fu QC, Cai X, Wu SM, Chen YG, Sun Y, Li J, Sui YH, Zhao W, Lu LG, Cao AP, Chen HZ (2009b) Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study. Zhonghua Gan Zang Bing Za Zhi 17(11):847-851
21. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1-6 (Pubitemid 26012496)
22. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JH (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352(9124):285 (Pubitemid 28340148)
23. Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC, Rowinsky EK (1993) Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr 15:39-46
24. Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC (2006) Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103(1):1-6 (Pubitemid 44374716)
25. Panday VR, Huizing MT, Willemse PH, De Graeff A, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH (1997) Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 24(4 Suppl 11):S11-34-S11-38
26. Park JH, Chi SC, Lee WS, Lee WM, Koo YB, Yong CS, Choi HG, Woo JS (2009) Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process. Arch Pharm Res 32(1):139-148
27. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108 (Pubitemid 40372904)
28. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9):699-708 (Pubitemid 30365530)
29. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54(21):5543-5546
30. Schellens JH, Malingre MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12(2):103-110
31. Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27(4):256-269 (Pubitemid 24315086)
32. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94(5):2031-2035 (Pubitemid 27113956)
33. Sun L, Shen J, Pang X, Lu L, Mao Y, Zeng M (2007) Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in Chinese healthy volunteers. J Clin Pharmacol 47(6):767-773 (Pubitemid 46800422)
34. Terauchi F, Moritake T, Yamamoto Y, Ogura H (2002) Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm. Int J Clin Oncol 7(6):356-360 (Pubitemid 36077318)
35. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW (1999) Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14(11):1093-1099
36. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW (2006) Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 41(9):1087-1094
37. Walle T, Walle UK, Kumar GN, Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23(4):506-512
38. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621(2):231-238
39. Wu X, Zhang L, Gurley E, Studer E, Shang J, Wang T, Wang C, Yan M, Jiang Z, Hylemon PB, Sanyal AJ, Pandak WM Jr, Zhou H (2008) Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 47(6):1905-1915 (Pubitemid 351945558)